Urogen Pharma (NASDAQ:URGN) Given Average Rating of “Moderate Buy” by Brokerages

Urogen Pharma (NASDAQ:URGN) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $33.00.

Several analysts have recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a report on Friday, January 23rd. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Urogen Pharma in a research note on Monday, October 27th.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $20.00 on Wednesday. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The company’s fifty day moving average is $22.46 and its 200-day moving average is $20.60. The company has a market capitalization of $936.20 million, a PE ratio of -5.78 and a beta of 1.32.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.03. The firm had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. On average, analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the transaction, the insider directly owned 139,025 shares of the company’s stock, valued at approximately $3,475,625. The trade was a 6.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. boosted its position in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the period. State of Wyoming bought a new position in Urogen Pharma in the third quarter valued at about $66,000. Russell Investments Group Ltd. increased its position in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the period. Finally, Strs Ohio bought a new stake in Urogen Pharma during the 3rd quarter worth about $76,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.